AsianScientist (Oct. 10, 2013) – Micell Technologies has entered into an agreement with Hefei Life Science for the clinical development, marketing and distribution of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) in China, including Hong Kong and Macau.
Hefei Life Science, based in Anhui Province in Eastern China, will fund and manage clinical development programs necessary to obtain regulatory approval for MiStent SES in the Chinese markets.
Under the agreement, Micell will manufacture and supply MiStent SES for clinical and commercial use. Sinopharm, a Shanghai-based company, will provide distribution and logistical support while Shanghai’s SinoMedCare will contribute marketing and sales support. The agreement includes annual purchase commitments commencing upon regulatory approval of MiStent SES for commercial sale in China.
“This agreement creates a strong opportunity for MiStent SES to enter the Chinese market and build upon our recent CE Mark approval in Europe,” said Arthur J. Benvenuto, Micell’s CEO and chairman. “Sinopharm and SinoMedCare bring strengths to this partnership with Hefei Life Science that we expect will make this important medical innovation in the coronary stent market readily accessible to patients in Greater China.”
——
Source: Micell Technologies.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
